Confined or spread disease-Spread with distant metastasis Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread with distant metastasis Posts on Medivizor

Combined S-1 chemotherapy improves the outcomes of patients with advanced colorectal cancer

Combined S-1 chemotherapy improves the outcomes of patients with advanced colorectal cancer

Posted by on Jul 1, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared two different chemotherapy treatments in metastatic colorectal cancer (mCRC; spread to other parts of the body). Researchers suggested that 24-hour infused irinotecan (Camptosar) plus oral S-1 (Teysuno) chemotherapy and bevacizumab (Avastin) is well tolerated and associated with improved outcomes. Some background...

Read More

Evaluating immune-related side effets in patients with advanced melanoma treated with immunotherapies

Evaluating immune-related side effets in patients with advanced melanoma treated with immunotherapies

Posted by on Jun 28, 2020 in Melanoma | 0 comments

In a nutshell The study monitored the occurrence of possible immune-related side effects (irSEs) in patients with advanced melanoma under single and combination therapy of ipilimumab (I; Yervoy), nivolumab (N; Opdivo), and pembrolizumab (P; Keytruda). The authors found that combination therapy increases the frequency of irSEs. Some background...

Read More

Tucatinib plus trastuzumab and capecitabine increased survival of patients with HER2-positive breast cancer spread to the brain

Tucatinib plus trastuzumab and capecitabine increased survival of patients with HER2-positive breast cancer spread to the brain

Posted by on Jun 14, 2020 in Breast cancer | 0 comments

In a nutshell This study looked at treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases (BM) with tucatinib (Tukysa) plus trastuzumab (Herceptin) and capecitabine (Xeloda). This study found that this treatment reduces the risk of cancer worsening in these...

Read More

The effectiveness and safety of regorafenib in older patients with advanced pretreated colorectal cancer

The effectiveness and safety of regorafenib in older patients with advanced pretreated colorectal cancer

Posted by on May 24, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of regorafenib (Stivarga) treatment in older patients with colorectal cancer (CRC). Researchers suggested that this treatment has similar effects in younger and older patients. Some background CRC is the third most common cancer worldwide. More than half are diagnosed in patients older...

Read More

Evaluating the effectiveness and safety of bevacizumab biosimilar in patients with metastatic colorectal cancer

Evaluating the effectiveness and safety of bevacizumab biosimilar in patients with metastatic colorectal cancer

Posted by on May 17, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of bevacizumab biosimilar (BE1040V) to the reference drug (Avastin) in the treatment of patients with metastatic colorectal cancer (mCRC). Researchers suggested that the effectiveness and safety of the biosimilar were similar to the reference drug bevacizumab. Some...

Read More

How common are allergic reactions to different biological therapies in patients with advanced melanoma?

How common are allergic reactions to different biological therapies in patients with advanced melanoma?

Posted by on May 16, 2020 in Melanoma | 0 comments

In a nutshell This study compared the frequency of allergic reactions to different doses of three biological therapies in patients with advanced melanoma. The authors found that different doses of the three drugs reduced the number of allergic reactions. Some background Biological therapy has significantly improved treatment results for patients...

Read More

Tucatinib in combination with trastuzumab and capecitabine for HER2 positive metastatic breast cancer

Posted by on May 6, 2020 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of tucatinib in combination with trastuzumab and capecitabine in patients with HER2 positive metastatic breast cancer who have had disease progression with other treatments.   This study concluded that this treatment combination was safe and...

Read More

Long-term outcomes of pertuzumab added to trastuzumab and docetaxel treatment for patients with advanced HER2-positive breast cancer

Posted by on Apr 7, 2020 in Breast cancer | 0 comments

In a nutshell This study looked at whether pertuzumab (Perjeta) benefits patients with metastatic HER2-positive breast cancer when added to trastuzumab (Herceptin) and docetaxel (Taxotere) treatment. They found that adding pertuzumab improved long-term patient outcomes. Some background Breast cancer can now be tested for some of the signals involved...

Read More

Metastasis surgery improves survival of patients with advanced colorectal cancer

Posted by on Jan 21, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the survival outcomes of patients who underwent surgery for colorectal cancer (CRC) metastasis (spread to other parts of the body). Researchers suggested that metastasis surgery is associated with survival improvement in these patients. Some background CRC is one of the most common cancers worldwide. A...

Read More

Robotic versus laparoscopic liver surgery is a safe treatment for metastatic colorectal cancer

Posted by on Dec 17, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of robotic-assisted liver surgery (RALS) compared to laparoscopic liver surgery (LLS) in advanced colorectal cancer. Researchers suggested that RALS is similarly safe and effective as LLS for these patients. Some background Colorectal cancer is one of the most common cancers worldwide....

Read More

High neutrophil-to-lymphocyte ratio in patients with melanoma treated with PD-1 inhibitor

Posted by on Dec 9, 2019 in Melanoma | 0 comments

In a nutshell This study wanted to find out if a high neutrophil-to-lymphocyte ratio (NLR) was related to the survival of patients with melanoma treated with PD-1 inhibitor treatment. The study found that the higher the NLR, the lower the chances of survival in these patients.  Some background One type of melanoma treatment involves...

Read More